Under the terms of the agreement, Medtronic will fund and provide its drug-device expertise as Nile executes on its Phase I clinical trial to assess the pharmacokinetics and phamacodynamics of cenderitide delivered through Medtronic diabetes pump technology. In the planned clinical trial, cenderitide will be delivered to heart failure patients for up to 24 hours through continuous subcutaneous infusion. Nile expects to complete the trial by the first quarter of 2012.
That is two weeks old and comes from the same 10K that states that they have enough cash to get them through the 4th Qtr. Are you late to the game, slow to read news, or just think this is the right time to suggest selling is the best thing to do, when in actuality, there is a good chance for a bump on the news coming from the ACC (Sunday presentation).